Program

12
2
1
1

Journal Year Published

5
5
4
1
1

Author

16
183
175
144
135
127
119
118
115
108
94
87
81
77
57
52
50
45
44
42
34

Category

9
5
1
1

Keyword

4
3
3
3
3
3
3
2
1
1
1
1
1
1
1
1
1
1
1
1

Journal

2
2
1
1
1
1
1
1
1
1
1
1
1
1

NCATS Publications

Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening.


Lin GL, et al.


Sci Transl Med , (11), 2019.

Article Pubmed

Sample image from publication page

High-potency ligands for DREADD imaging and activation in rodents and monkeys.


Bonaventura J, Eldridge MAG, Hu F, Gomez JL, Sanchez-Soto M, Abramyan AM, Lam S, Boehm MA, Ruiz C, Farrell MR, Moreno A, Galal Faress IM, Andersen N, Lin JY, Moaddel R, Morris P, Shi L, Sibley DR, Mahler SV, Nabavi S, Pomper MG, Bonci A, Horti AG, Richmond BJ, Michaelides M


Nat Commun , (10), 4627, 2019.

Article Pubmed

Sample image from publication page

(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses.


Zanos P, Highland JN, Liu X, Troppoli TA, Georgiou P, Lovett J, Morris P, Stewart BW, Thomas C, Thompson SM, Moaddel R, Gould TD


Br. J. Pharmacol. , (176), 2573-2592, 2019.

Article Pubmed

Sample image from publication page

(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions.


Zanos P, Highland JN, Stewart BW, Georgiou P, Jenne CE, Lovett J, Morris P, Thomas C, Moaddel R, Zarate CA, Gould TD


Proc. Natl. Acad. Sci. U.S.A. , (116), 6441-6450, 2019.

Article Pubmed

Sample image from publication page

Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function.


Lumsden EW, Troppoli TA, Myers SJ, Zanos P, Aracava Y, Kehr J, Lovett J, Kim S, Wang FH, Schmidt S, Jenne CE, Yuan P, Morris P, Thomas C, Zarate CA, Moaddel R, Traynelis SF, Pereira EFR, Thompson SM, Albuquerque EX, Gould TD


Proc. Natl. Acad. Sci. U.S.A. , (116), 5160-5169, 2019.

Article Pubmed

Sample image from publication page

Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of ( 2R,6R)-hydroxynorketamine.


Highland JN, Morris P, Zanos P, Lovett J, Ghosh S, Wang A, Zarate CA, Thomas C, Moaddel R, Gould TD


J. Psychopharmacol. (Oxford) , 269881118812095, 2018.

Article Pubmed

Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects.


Moaddel R, Shardell M, Khadeer M, Lovett J, Kadriu B, Ravichandran S, Morris P, Yuan P, Thomas C, Gould TD, Ferrucci L, Zarate CA


Psychopharmacology (Berl.) , (235), 3017-3030, 2018.

Article Pubmed

Sample image from publication page

miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential.


Meyer SE, Muench DE, Rogers AM, Newkold TJ, Orr E, O'Brien E, Perentesis JP, Doench JG, Lal A, Morris P, Thomas C, Lieberman J, McGlinn E, Aronow BJ, Salomonis N, Grimes HL


J. Exp. Med. , (215), 2115-2136, 2018.

Article Pubmed

Sample image from publication page

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.


Zanos P, Moaddel R, Morris P, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas C, Zarate CA, Gould TD


Pharmacol. Rev. , (70), 621-660, 2018.

Article Pubmed

Sample image from publication page

Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures.


Dyall J, Nelson EA, DeWald LE, Guha R, Hart BJ, Zhou H, Postnikova E, Logue J, Vargas WM, Gross R, Michelotti J, Deiuliis N, Bennett RS, Crozier I, Holbrook MR, Morris P, Klumpp-Thomas C, McKnight C, Mierzwa T, Shinn P, Glass PJ, Johansen LM, Jahrling PB, Hensley LE, Olinger GG, Thomas C, White JM


J. Infect. Dis. , 2018.

Article Pubmed

Sample image from publication page